UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2015
ContraVir Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 000-55020 | | 46-2783806 |
(State or other jurisdiction | | (Commission | | IRS Employer |
of incorporation or organization) | | File Number) | | Identification No.) |
399 Thornall Street, First Floor
Edison, NJ 08837
(Address of principal executive offices)
Registrant’s telephone number, including area code: (732) 902-4000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On February 4, 2015, ContraVir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, “Nucleoside Phosphonate Salts.” The patent covers composition of matter for CMX157, the Company’s Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which the Company is developing to treat hepatitis B virus (HBV). The new patent extends the Company’s intellectual property protection for CMX157 to at least 2031. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 ContraVir Pharmaceuticals, Inc. Press Release dated February 4, 2015
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 4, 2015
| CONTRAVIR PHARMACEUTICALS, INC. |
| | |
| | |
| By: | /s/ James Sapirstein |
| James Sapirstein |
| Chief Executive Officer |
2
